Thanks for filing me in, especially since the sound on my end was all garbled.
With continued good news like this, it's practically a certainty that the pps will hit zero right quick!
anyone else having trouble with the distorted unintelligible sound?
1. Hand held device being introduced this week, will be commercially available in Q3
2. break even when annual revenue per sales person reaches 2M
3. 150 patients for film, between 450 -800 for Pillar 3
4. sales staff including "educators" to total 200
5. SPY in 750 hospitals, growing 50 per quarter
6. familiarity with SPY becoming part of resident's training
Not at all happy with the non response re: replacing poorly performing sales people.
I'll redouble my efforts to speak with Steve Kilmer.
My understanding was that Arun and Roger were prepared to eliminate the lower quartile of salespeople for under performance. That's what I'm most interested in. Everything else was discussed at Needham.
Agreed, disappointed about the lack of revenue news for the current quarter.
Enrollments picking up, with Film results expected in Q4 and Pillar results expected at SAGES, Q1.
International on track for H2 with the European socialists and Asia expected to kick in.
2nd molecule to be introduced this year, 3rd molecule next year.
Sales team still at 100 on the way to 120.
So we're still in hurry up and wait mode.
(from your link on IV).... Reason for the Shortage, Hub Pharmaceuticals states the reason for the shortage was increased demand.
(from my earlier post....) Is it coming from increased use of SPY?
This seems to go with my theory that the shortage is due to increased use of SPY.
Never heard of this pharmacist group before.
What is the source of this increased demand? Is it coming from increased use of SPY? In any case it's good to know that the company has a backup in place. Just wondering...could this be the reason for the run up in the shares on heavy volume today?
I'm sure that top management is well aware that differences exist in the various sales environments in the country and OUS. However, when you consider the things that remain the same----clinical studies and publications, reimbursements from CMS and the clear advantages of SPY, I think that in this case, patience is definitely NOT a virtue . We've already waited through 9-12 months of training and education. It's time for results! Of course firing some sales staff means starting the timeline from scratch. Who does the hiring? Is it VP of sales Tom Tamburrino, or is it Arun/Roger/Rick?
Maybe I'll place a call to Steve Kilmer, agreed?
I also heard the webcast from this morning.
I was struck by Roger's comments on the sales force.
With the top quarter doing extremely well, the top half doing reasonably well and the lower half performing abysmally, Roger said (in reference to the lower half) that at this point it is "on them, and not on us" to shoulder the blame for their sub par results. I sensed that he was losing patience with this group and more than ready to fire them and replace them with new people. Indeed, he added that there was "good money" to be made, and that he was reviewing new applicants' resumes. I thought this exchange was the most significant part of the whole presentation.
"but the growing short interest peaked at 7.227M shares in the latest reporting period (Oct 15" Correction: please ignore "the latest reporting period"
Stryker was a subject on both the cc of Q4, 2014 and Q1 of 2015, when the short interest was 4.452M . SAGES kept the buzz going for a while, but the growing short interest peaked at 7.227M shares in the latest reporting period (Oct 15). So perhaps you're right about the institutions causing the extremely volatility in the shares. Interestingly, their holdings remained essentially flat. To me, that's a sign of confidence. So I'm willing to stay patient. Perhaps the next needle mover will be the results of FILM and PILLAR 3. I also took note that Arun mentioned a new separate pillar type study in Europe. It tells me that SPY is the way of the future.
I think back to Investors day November 2015 when Tom Tamburrino (VP Sales) told me that "in 365 days" i.e. (the next Investors day) that we would see results. He seemed so confident...